Global Infectious Diseases in-Vitro Diagnostics (IVD) Market to reach USD 73 billion by 2027

Global Infectious Diseases in-Vitro Diagnostics (IVD) Market Size study, by Product (Instruments, Reagent, Services), by Technology (Immunoassay, Molecular Diagnostics, Microbiology, Others), by Application (Streptococcus, Clostridium Difficile, Carbapenem-resistant enterobacterial testing (CRE), Respiratory virus, Tuberculosis (TB) & drug-resistant TB, Human Immunodeficiency Virus (HIV), Gonorrhea, Chlamydia, Others), by End-Use (Point of Care, Central Laboratories, Others) and Regional Forecasts 2020-2027
Product Code:  HALMD_55686319
Chapter 1.	Executive Summary 
1.1.	Market Snapshot
1.2.	Global & Segmental Market Estimates & Forecasts, 2018-2027 (USD Billion)
1.2.1.	Infectious Diseases in-Vitro Diagnostics (IVD) Market, by Region, 2018-2027 (USD Billion)
1.2.2.	Infectious Diseases in-Vitro Diagnostics (IVD) Market, by Product, 2018-2027 (USD Billion)
1.2.3.	Infectious Diseases in-Vitro Diagnostics (IVD) Market, by Technology, 2018-2027 (USD Billion)
1.2.4.	Infectious Diseases in-Vitro Diagnostics (IVD) Market, by Application, 2018-2027 (USD Billion)
1.2.5.	Infectious Diseases in-Vitro Diagnostics (IVD) Market, by End-Use, 2018-2027 (USD Billion)
1.3.	Key Trends
1.4.	Estimation Methodology
1.5.	Research Assumption
Chapter 2.	Global Infectious Diseases in-Vitro Diagnostics (IVD) Market Definition and Scope 
2.1.	Objective of the Study
2.2.	Market Definition & Scope
2.2.1.	Scope of the Study
2.2.2.	Industry Evolution
2.3.	Years Considered for the Study
2.4.	Currency Conversion Rates
Chapter 3.	Global Infectious Diseases in-Vitro Diagnostics (IVD) Market Dynamics	
3.1.	Infectious Diseases in-Vitro Diagnostics (IVD) Market Impact Analysis (2018-2027)
3.1.1.	Market Drivers
3.1.2.	Market Challenges
3.1.3.	Market Opportunities
Chapter 4.	Global Infectious Diseases in-Vitro Diagnostics (IVD) Market Industry Analysis
4.1.	Porter’s 5 Force Model
4.1.1.	Bargaining Power of Suppliers
4.1.2.	Bargaining Power of Buyers
4.1.3.	Threat of New Entrants
4.1.4.	Threat of Substitutes
4.1.5.	Competitive Rivalry
4.1.6.	Futuristic Approach to Porter’s 5 Force Model (2017-2027)
4.2.	PEST Analysis
4.2.1.	Political 
4.2.2.	Economical
4.2.3.	Social 
4.2.4.	Technological 
4.3.	Investment Adoption Model
4.4.	Analyst Recommendation & Conclusion
Chapter 5.	Global Infectious Diseases in-Vitro Diagnostics (IVD) Market, by Product 
5.1.	Market Snapshot 
5.2.	Global Infectious Diseases in-Vitro Diagnostics (IVD) Market by Product, Performance - Potential Analysis
5.3.	Global Infectious Diseases in-Vitro Diagnostics (IVD) Market Estimates & Forecasts by Product 2017-2027 (USD Billion)
5.4.	Infectious Diseases in-Vitro Diagnostics (IVD) Market, Sub Segment Analysis
5.4.1.	Instruments
5.4.2.	Reagent
5.4.3.	Services
Chapter 6.	Global Infectious Diseases in-Vitro Diagnostics (IVD) Market, by Technology
6.1.	Market Snapshot 
6.2.	Global Infectious Diseases in-Vitro Diagnostics (IVD) Market by Technology, Performance - Potential Analysis
6.3.	Global Infectious Diseases in-Vitro Diagnostics (IVD) Market Estimates & Forecasts by Technology 2017-2027 (USD Billion)
6.4.	Infectious Diseases in-Vitro Diagnostics (IVD) Market, Sub Segment Analysis
6.4.1.	Immunoassay
6.4.2.	Molecular Diagnostics
6.4.3.	Microbiology
6.4.4.	Others
Chapter 7.	Global Infectious Diseases in-Vitro Diagnostics (IVD) Market, by Application          
7.1.	Market Snapshot 
7.2.	Global Infectious Diseases in-Vitro Diagnostics (IVD) Market by Application, Performance - Potential Analysis
7.3.	Global Infectious Diseases in-Vitro Diagnostics (IVD) Market Estimates & Forecasts by Application 2017-2027 (USD Billion)
7.4.	Infectious Diseases in-Vitro Diagnostics (IVD) Market, Sub Segment Analysis
7.4.1.	Streptococcus
7.4.2.	Clostridium Difficile
7.4.3.	Carbapenem-resistant enterobacterial testing (CRE)
7.4.4.	Respiratory virus
7.4.5.	Tuberculosis (TB) & drug-resistant TB
7.4.6.	Human Immunodeficiency Virus (HIV)
7.4.7.	Gonorrhea
7.4.8.	Chlamydia
7.4.9.	Others
Chapter 8.	Global Infectious Diseases in-Vitro Diagnostics (IVD) Market, by End-Use
8.1.	Market Snapshot 
8.2.	Global Infectious Diseases in-Vitro Diagnostics (IVD) Market by End-Use - Potential Analysis
8.3.	Global Infectious Diseases in-Vitro Diagnostics (IVD) Market Estimates & Forecasts by End-Use 2017-2027 (USD Billion)
8.4.	Infectious Diseases in-Vitro Diagnostics (IVD) Market, Sub Segment Analysis
8.4.1.	Point of Care
8.4.2.	Central Laboratories
8.4.3.	Others
Chapter 9.	Global Infectious Diseases in-Vitro Diagnostics (IVD) Market, Regional Analysis
9.1.	Infectious Diseases in-Vitro Diagnostics (IVD) Market, Regional Market Snapshot 
9.2.	North America Infectious Diseases in-Vitro Diagnostics (IVD) Market 
9.2.1.	U.S. Infectious Diseases in-Vitro Diagnostics (IVD) Market
9.2.1.1.	Product breakdown estimates & forecasts, 2017-2027
9.2.1.2.	Technology breakdown estimates & forecasts, 2017-2027
9.2.1.3.	Application breakdown estimates & forecasts, 2017-2027
9.2.1.4.	End-Use breakdown estimates & forecasts, 2017-2027
9.2.2.	Canada Infectious Diseases in-Vitro Diagnostics (IVD) Market
9.3.	Europe Infectious Diseases in-Vitro Diagnostics (IVD) Market Snapshot
9.3.1.	U.K. Infectious Diseases in-Vitro Diagnostics (IVD) Market 
9.3.2.	Germany Infectious Diseases in-Vitro Diagnostics (IVD) Market
9.3.3.	France Infectious Diseases in-Vitro Diagnostics (IVD) Market
9.3.4.	Spain Infectious Diseases in-Vitro Diagnostics (IVD) Market
9.3.5.	Italy Infectious Diseases in-Vitro Diagnostics (IVD) Market
9.3.6.	Rest of Europe Infectious Diseases in-Vitro Diagnostics (IVD) Market
9.4.	Asia-Pacific Infectious Diseases in-Vitro Diagnostics (IVD) Market Snapshot
9.4.1.	China Infectious Diseases in-Vitro Diagnostics (IVD) Market 
9.4.2.	India Infectious Diseases in-Vitro Diagnostics (IVD) Market 
9.4.3.	Japan Infectious Diseases in-Vitro Diagnostics (IVD) Market
9.4.4.	Australia Infectious Diseases in-Vitro Diagnostics (IVD) Market
9.4.5.	South Korea Infectious Diseases in-Vitro Diagnostics (IVD) Market
9.4.6.	Rest of Asia Pacific Infectious Diseases in-Vitro Diagnostics (IVD) Market
9.5.	Latin America Infectious Diseases in-Vitro Diagnostics (IVD) Market Snapshot
9.5.1.	Brazil Infectious Diseases in-Vitro Diagnostics (IVD) Market
9.5.2.	Mexico Infectious Diseases in-Vitro Diagnostics (IVD) Market
9.6.	Rest of The World Infectious Diseases in-Vitro Diagnostics (IVD) Market
Chapter 10.	Competitive Intelligence
10.1.	Top Market Strategies
10.2.	Company Profiles
10.2.1.	Becton, Dickinson and Company
10.2.1.1.	Key Information
10.2.1.2.	Overview
10.2.1.3.	Financial (Subject to Data Availability)
10.2.1.4.	Product Summary
10.2.1.5.	Recent Developments
10.2.2.	BioMérieux SA
10.2.3.	Abbott Laboratories
10.2.4.	Quidel Corporation
10.2.5.	OraSure Technologies, Inc.
10.2.6.	Hologic Inc. (Gen Probe)
10.2.7.	Qiagen
10.2.8.	F. Hoffmann-La Roche Ltd.
10.2.9.	Siemens Healthcare GmbH
10.2.10.	Bio-Rad Laboratories, Inc.
Chapter 11.	Research Process
11.1.	Research Process
11.1.1.	Data Mining
11.1.2.	Analysis
11.1.3.	Market Estimation
11.1.4.	Validation
11.1.5.	Publishing
11.2.	Research Attributes
11.3.	Research Assumption

Global Infectious Diseases in-Vitro Diagnostics (IVD) Market is valued at approximately USD 54 billion in 2019 and is anticipated to grow with a healthy growth rate of more than 3.8% over the forecast period 2020-2027. Infectious Diseases in-Vitro Diagnostics (IVD) is a type of medical devices, which needs the use of reagents and assays to treat a medical condition. The information shown through these diagnostic tools helps physicians in productive management of medical settings in each stage. In addition, the use and handling of in-vitro diagnostics needs significant technical expertise, and therefore, instruments are utilized in specific medical facilities to perform a diagnosis of diseases. For example, infectious diseases IVD products are frequently using in many healthcare facilities, such as point-of care centers, standalone laboratories, and hospitals. Moreover, there have been significant developments have been advanced in these products that have enabled a paradigm shift from point of care testing to laboratory testing, which is assisting in expansion of infectious diseases IVD market. Furthermore, the rise in prevalence of infectious diseases in the developed and developing region, along with the increasing government support and consumer awareness in regards of faster diagnostics are the few factors responsible for the high CAGR of the market during the forecast period. For instance, according to the Avert organization, in 2018, nearly 37.9 million individuals were affected by HIV (including 1.7 million children), with a global prevalence rate of HIV is estimated nearly 0.8% among adults. Similarly, the U.S. Department of Health & Human Services has valued about 21.7 million people living with HIV in 2017, signifying a surge of 2.3 million from 2016. Likewise, as per the survey of Center for Disease Control and Prevention, the symptomatic illness of influenza in the US is nearly 30,000,000 during 2016-17 and is increased to approximately 49,000,000 in 2017-18. This, in turn, is likely to strengthen the demand for Infectious Diseases in-Vitro Diagnostics (IVD) products, globally. However, the high prices of IVD testing is one of the major factors limiting the market growth over the forecast period of 2020-2027.

The regional analysis of the global Infectious Diseases in-Vitro Diagnostics (IVD) market is considered for the key regions such as Asia Pacific, North America, Europe, Latin America, and Rest of the World. North America is the leading/significant region across the world in terms of market share owing to the rising demand for the Point-of-care and molecular diagnostic devices, along with the rise in presence of market vendors in the region. Whereas, Asia-Pacific is anticipated to exhibit the highest growth rate / CAGR over the forecast period 2020-2027. Factors such as growing prevalence of infectious diseases along with growing healthcare infrastructure in developing countries, such as China and India, are the few factors creating lucrative growth opportunities for the Infectious Diseases in-Vitro Diagnostics (IVD) market in the region.

Major market player included in this report are:
Becton, Dickinson and Company
BioMérieux SA
Abbott Laboratories
Quidel Corporation
OraSure Technologies, Inc.
Hologic Inc. (Gen Probe)
Qiagen
F. Hoffmann-La Roche Ltd.
Siemens Healthcare GmbH
Bio-Rad Laboratories, Inc.

The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming eight years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within each of the regions and countries involved in the study. Furthermore, the report also caters the detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, the report shall also incorporate available opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players. The detailed segments and sub-segment of the market are explained below:

By Product:
Instruments
Reagent
Services

By Technology:
Immunoassay
Molecular Diagnostics
Microbiology
Others

By Application:
Streptococcus
Clostridium Difficile
Carbapenem-resistant enterobacterial testing (CRE)
Respiratory virus
Tuberculosis (TB) & drug-resistant TB
Human Immunodeficiency Virus (HIV)
Gonorrhea
Chlamydia
Others

By End-Use:
Point of Care
Central Laboratories
Others

By Region:
North America
U.S.
Canada
Europe
UK
Germany
France
Spain
Italy
ROE

Asia Pacific
China
India
Japan
Australia
South Korea
RoAPAC
Latin America
Brazil
Mexico
Rest of the World

Furthermore, years considered for the study are as follows:

Historical year – 2017, 2018
Base year – 2019
Forecast period – 2020 to 2027

Target Audience of the Global Infectious Diseases in-Vitro Diagnostics (IVD) Market in Market Study:

Key Consulting Companies & Advisors
Large, medium-sized, and small enterprises
Venture capitalists
Value-Added Resellers (VARs)
Third-party knowledge providers
Investment bankers
Investors


We offer 10% free customization including country-level data, niche applications and competitive landscape with every report. This also includes a 30 minute free analyst discussion post report purchase.

Full Name*

Business Email* (Please avoid generic email IDs such as gmail, yahoo)

Phone* (Please Affix Country Code)

Need specific market information? To get a customized report, please share your exact research requirements.



Loading…